Watch full video<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"Shin Kawamata, MD, PhD, Director of the R&D Center for Cell Therapy at the FBRI (Kobe, Japan) stresses the importance of controlling the quality of iPSC banks at a very early stage, including CiRA cell lines, to meet safety guidelines at clinical stages.<\/p>\n","protected":false},"author":1,"featured_media":2552,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"aioseo_notices":[],"yoast_head":"\n
Quality Control of iPSC-derived clinical products - Stem Cells & Cell Therapy Blog I In the Stem Cell Jungle I iPSCs I TreeFrog Therapeutics<\/title>\n\n\n\n\n\n\n\n\n\n\n\t\n\t\n\t\n\n\n\n\n